BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-107@pharmaconomics
DTSTAMP:20260707T034602Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:IBRX Phase 2 — Gemcitabine (estimated date)
DESCRIPTION:Phase 2 trial results for Gemcitabine in Platinum-resistant Ovarian Cancer are due ~ May 31\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06710288\n\nTrack it: https://www.pharmaconomics.com/e/107
URL:https://www.pharmaconomics.com/e/107
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IBRX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR